Peter Chambré
Chairman of the Board
Peter is a knowledgeable and experienced pharmaceutical industry executive. A brief summary of his background and current positions:
- Chariman of ApaTech Ltd., a world leader in synthetic bone graft technologies
- Director of BTG plc and Spectrics pls, both listed on the London Stock Exchange
- Advisor to 3i Group plc
- Chief Exectuive officer (CEO) of Cambridge Antibody Technology plc, a leading biopharmaceutical company discovering and developing antibody therapeutics, from 2002 until its acquisition by AstraZeneca in July 2006
- Chief Operating Officer (COO) at Celera Genomics Group
- Chief Executive Officer (CEO) at Bespak plc, the drug delivery group
- Senior positions at Bain & Company and Unilever plc
